Project Grant K22CA292568
Award Date 9/1/25
Completion Date 8/31/28
Dollars Obligated $184K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Salt Lake City, UT 84112, USA
Similar Awards
- The National Cancer Institute (NCI) awarded a $547,945 Project Grant under CFDA 93.396 (Cancer Biology Research) to The Johns Hopkins University to conduct research on the pathogenesis of immune checkpoint inhibitor-induced myocarditis. The project aims to investigate how biological factors such as prior cardiac injury, age, and sex modulate the risk of this adverse event, which occurs in 1-2% of cancer patients receiving immune checkpoint inhibitor therapy but can be fatal in up to 50% of...
- This Project Grant award of $754,511 from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research at the Jackson Laboratory to discover host genetic factors that influence response to immune checkpoint inhibitor (ICI) cancer treatments. The project aims to: Expand and refine a mouse experimental platform to map quantitative trait loci (QTLs) associated with ICI response, focusing on defining the genetic mechanisms behind epistatic interactions. Challenge top...
- This Project Grant, awarded by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program), provides $121,857 to the University of Pittsburgh to systematically investigate the impact of anti-cancer drugs on T cells within the tumor microenvironment. The award aims to identify novel drug combinations that can overcome resistance to immune checkpoint blockade therapies in cancer treatment. Specifically, the research will involve in silico screening of anti-cancer drugs for their...
- This federal Project Grant award of $312,892 was provided by the National Cancer Institute (NCI) under the Cancer Research Manpower (CFDA 93.398) program. The grant supports research at Duke University to study the role of type 3 innate lymphoid cells (ILC3s) in regulating the melanoma tumor microenvironment. The goal is to understand how ILC3s impact the effectiveness of immune checkpoint inhibitor (ICI) therapy for advanced melanoma patients, as the majority do not respond to ICI treatment....
- This Project Grant award of $124,134 from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports research to investigate the mechanisms of pathogenesis and treatment response in immune checkpoint inhibitor-induced colitis. The research aims to define the role of specific T cell subsets recruited from circulation in promoting inflammation and mediating therapeutic response in this condition, which can occur in up to 40% of cancer patients receiving immune checkpoint...
- The Project Grant award of $1,387,727.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) will support the "Integrated Immunomodulatory Analysis of LAG3 Inhibition in Renal Cell Carcinoma" research project conducted by the Sloan-Kettering Institute for Cancer Research in New York, NY. The award period runs from September 1, 2025 to August 31, 2029. The research aims to advance the scientific understanding and develop innovative diagnostic...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $3,182,665 to The Washington University to investigate how natural killer (NK) cells can subvert the effectiveness of immune checkpoint therapy for cancer treatment. The key objectives are to: 1) elucidate the mechanisms by which NK cells constrain the efficacy of immune checkpoint therapy, 2) evaluate the contribution of the NKG2D receptor in this process, and 3) translate the findings...
- This federal Project Grant award of $663,340 from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research to elucidate the mechanisms by which the ablation of intratumoral regulatory T cells can mobilize NK cells and CD4 T cells to control MHC I-deficient tumors. The research aims to determine how CD4 T cell help enhances the antitumor function of NK cells, including the role of cytokines like IL-2 and IL-15, as well as test whether intratumoral Treg depletion...
- This $495,715 Project Grant awarded by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research by the Sloan-Kettering Institute for Cancer Research to decipher the pathogenesis and therapeutic vulnerabilities of acute myeloid leukemia (AML) driven by germline RUNX1 mutations. The project aims to develop faithful preclinical models, including genetically engineered mouse models and patient-derived xenografts, to study the genetic events and disease progression from...
- This federal Project Grant award of $100,760 from the National Cancer Institute's (NCI) Cancer Research Manpower program (CFDA 93.398) supports research conducted by the Sloan-Kettering Institute for Cancer Research in New York City. The project aims to engineer biomaterials that can modulate the tumor immune microenvironment, with a focus on developing an innovative RNA interference (RNAi) therapy to inhibit the cancer-promoting factors cyclophilin A and E-selectin in multiple myeloma....